# Paolo Gisondi

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/3246719/paolo-gisondi-publications-by-citations.pdf

Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81 7,807 46 239 h-index g-index citations papers 6.22 9,650 265 3.5 L-index avg, IF ext. citations ext. papers

| #   | Paper  | IF                | Citations |
|-----|--|-------------------|-----------|
| 239 | European S3-guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23 Suppl 2, 1-70   | 4.6               | 586       |
| 238 | Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , <b>2011</b> , 303, 1-10   | 3.3               | 527       |
| 237 | Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.<br>British Journal of Dermatology, <b>2007</b> , 157, 68-73  | 4                 | 445       |
| 236 | European S3-Guidelines on the systemic treatment of psoriasis vulgarisUpdate 2015Short versionEDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 2277-94  | 4.6               | 271       |
| 235 | Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 26-30   | 2.4               | 190       |
| 234 | Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 251-265.e   | 1 <del>19</del> 5 | 186       |
| 233 | Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 758-64   | 13.4              | 179       |
| 232 | Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. <i>American Journal of Clinical Nutrition</i> , <b>2008</b> , 88, 1242-7 | 7                 | 168       |
| 231 | The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1549  | 8.4               | 164       |
| 230 | Prevalence of symptoms experienced by patients with different clinical types of psoriasis. <i>British Journal of Dermatology</i> , <b>2004</b> , 151, 594-9  | 4                 | 146       |
| 229 | Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2008</b> , 22, 341-4                                       | 4.6               | 137       |
| 228 | Survival rate of antitumour necrosis factor-treatments for psoriasis in routine dermatological practice: a multicentre observational study. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 666-72  | 4                 | 123       |
| 227 | Psoriasis and the metabolic syndrome. <i>Clinics in Dermatology</i> , <b>2018</b> , 36, 21-28  | 3                 | 120       |
| 226 | Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 553-6  | 2.4               | 113       |
| 225 | Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 1345-   | . <del>9</del> 1  | 106       |
| 224 | Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2006</b> , 155, 1165-9   | 4                 | 96        |
| 223 | Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 774-790  | 4.6               | 94        |

| 222 | Chronic plaque psoriasis is associated with increased arterial stiffness. <i>Dermatology</i> , <b>2009</b> , 218, 110-3   | 4.4               | 93 |
|-----|---|-------------------|----|
| 221 | Impairment of sexual life in patients with psoriasis. <i>Dermatology</i> , <b>2007</b> , 214, 144-50  | 4.4               | 92 |
| 220 | Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology, 2012, 166, 50   | 5 <sub>4</sub> 10 | 89 |
| 219 | European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1951-1963 | 4.6               | 86 |
| 218 | The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. <i>Rheumatology</i> , <b>2012</b> , 51, 2058-63   | 3.9               | 86 |
| 217 | H1 histamine receptor mediates inflammatory responses in human keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2004</b> , 114, 1176-82  | 11.5              | 84 |
| 216 | The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 373-374                                | 4                 | 83 |
| 215 | Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 60-71  | 11.5              | 77 |
| 214 | Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2009</b> , 35, 313-24  | 5.3               | 74 |
| 213 | Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 775-83   | 4                 | 68 |
| 212 | Biologic therapies in psoriasis: a new therapeutic approach. <i>Autoimmunity Reviews</i> , <b>2007</b> , 6, 515-9   | 13.6              | 67 |
| 211 | Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. <i>European Journal of Dermatology</i> , <b>2005</b> , 15, 279-83  | 0.8               | 65 |
| 210 | Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, e30-41                  | 4.6               | 63 |
| 209 | Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 2691-2  | 4.1               | 63 |
| 208 | The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 992-5                          | 2.4               | 60 |
| 207 | Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1196-1201  | 4.6               | 60 |
| 206 | Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2499-2504  | 4.6               | 58 |
| 205 | Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a  |                   | 58 |

| 204 | Management of moderate to severe psoriasis in patients with metabolic comorbidities. <i>Frontiers in Medicine</i> , <b>2015</b> , 2, 1   | 4.9 | 56 |
|-----|--|-----|----|
| 203 | Treatment Approaches to Moderate to Severe Psoriasis. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,   | 6.3 | 54 |
| 202 | Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 749-55  | 4   | 53 |
| 201 | Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 126-31  | 4.5 | 52 |
| 200 | Immunogenicity of anti-TNFItherapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1673-82  | 5.4 | 51 |
| 199 | Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 1085-96   | 6.4 | 48 |
| 198 | Usefulness of the framingham risk score in patients with chronic psoriasis. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 1754-7  | 3   | 47 |
| 197 | Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 217  | 6.3 | 47 |
| 196 | Psoriasis and systemic inflammation: underdiagnosed enthesopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23 Suppl 1, 3-8  | 4.6 | 46 |
| 195 | Immunoregulation of allergic contact dermatitis. <i>Journal of Dermatology</i> , <b>2004</b> , 31, 264-70  | 1.6 | 46 |
| 194 | Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.<br>Journal of the American Academy of Dermatology, <b>2020</b> , 82, 117-122  | 4.5 | 46 |
| 193 | Folic acid in general medicine and dermatology. <i>Journal of Dermatological Treatment</i> , <b>2007</b> , 18, 138-46  | 2.8 | 45 |
| 192 | Pimecrolimus in dermatology: atopic dermatitis and beyond. <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 969-74  | 2.9 | 41 |
| 191 | Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 285-287 | 4.5 | 40 |
| 190 | Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 282-7   | 4.6 | 40 |
| 189 | Hyperuricemia in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 127-30  | 4.5 | 38 |
| 188 | Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. <i>Immunologic Research</i> , <b>2013</b> , 56, 382-9  | 4.3 | 37 |
| 187 | Ultrasonography reveals nail thickening in patients with chronic plaque psoriasis. <i>Archives of Dermatological Research</i> , <b>2012</b> , 304, 727-32  | 3.3 | 37 |

## (2021-2014)

| 186 | Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. <i>Dermatology</i> , <b>2014</b> , 228, 78-85  | 4.4 | 36 |  |
|-----|--|-----|----|--|
| 185 | EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2461-2498  | 4.6 | 36 |  |
| 184 | Phenotypes of atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2011, 9, 12-20   | 1.2 | 35 |  |
| 183 | Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1591-1597   | 2.4 | 33 |  |
| 182 | Targeting tumor necrosis factor-alpha in the therapy of psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , <b>2004</b> , 3, 175-83   |     | 33 |  |
| 181 | Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 117  | 5.6 | 32 |  |
| 180 | Metabolic comorbidities and psoriasis. Acta Dermatovenerologica Croatica, 2010, 18, 297-304  | 0.5 | 32 |  |
| 179 | Advanced Glycation End Products in the Pathogenesis of Psoriasis. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,   | 6.3 | 31 |  |
| 178 | Microcirculatory modifications of psoriatic lesions during topical therapy. <i>Skin Research and Technology</i> , <b>2009</b> , 15, 135-8  | 1.9 | 30 |  |
| 177 | A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 197-205 | 4   | 29 |  |
| 176 | The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1695-1706  | 4.6 | 29 |  |
| 175 | Considerations for Systemic Treatment of Psoriasis in Obese Patients. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 609-615  | 7.1 | 29 |  |
| 174 | Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. <i>Acta Dermato-Venereologica</i> , <b>2006</b> , 86, 528-34  | 2.2 | 29 |  |
| 173 | Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 271-277                                      | 5.4 | 29 |  |
| 172 | C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2010</b> , 23, 1195-202  | 3   | 28 |  |
| 171 | Efficacy of a single educative intervention in patients with chronic plaque psoriasis. <i>Dermatology</i> , <b>2009</b> , 219, 316-21  | 4.4 | 28 |  |
| 170 | Perception of disease and doctor-patient relationship experienced by patients with psoriasis: a questionnaire-based study. <i>American Journal of Clinical Dermatology</i> , <b>2009</b> , 10, 325-30  | 7.1 | 28 |  |
| 169 | Evidence for a Rwindow of opportunityRin hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 133-140   | 4   | 28 |  |

| 168 | Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis. <i>Pediatric Dermatology</i> , <b>2016</b> , 33, 530-5   | 1.9  | 27 |
|-----|---|------|----|
| 167 | The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1356-1363  | 4.5  | 27 |
| 166 | Psoriasis, the liver, and the gastrointestinal tract. <i>Dermatologic Therapy</i> , <b>2010</b> , 23, 155-9   | 2.2  | 26 |
| 165 | Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. <i>Journal of Dermatological Treatment</i> , <b>2011</b> , 22, 366-71   | 2.8  | 25 |
| 164 | Autoimmune progesterone dermatitis. <i>Gynecological Endocrinology</i> , <b>2006</b> , 22, 54-6   | 2.4  | 25 |
| 163 | Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors[for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 567-579  | 7.1  | 25 |
| 162 | Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1853-1859 | 4.6  | 24 |
| 161 | State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , <b>2019</b> , 46, 90-99   | 5.1  | 24 |
| 160 | Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: AlNorthern Italy experience. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 558-560.e1  | 11.5 | 24 |
| 159 | Adult atopic dermatitis: a review. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 403-11  | 0.8  | 24 |
| 158 | Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. <i>Journal of Dermatological Treatment</i> , <b>2016</b> , 27, 395-8   | 2.8  | 23 |
| 157 | Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study. <i>Dermatology</i> , <b>2012</b> , 224, 31-7   | 4.4  | 23 |
| 156 | Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.<br>Journal of Dermatological Treatment, <b>2013</b> , 24, 305-11  | 2.8  | 22 |
| 155 | Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1613-1620   | 4    | 22 |
| 154 | Incidence of respiratory and allergic symptoms in Italian and immigrant children. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 204-10   | 4.6  | 22 |
| 153 | Cardiometabolic comorbidities and the approach to patients with psoriasis. <i>Actas Dermo-sifiliogr</i> (Gicas, <b>2009</b> , 100 Suppl 2, 14-21  | 0.5  | 22 |
| 152 | Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. <i>Dermatologic Therapy</i> , <b>2008</b> , 21 Suppl 1, S31-8  | 2.2  | 22 |
| 151 | Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 1547-1548   | 4    | 22 |

| 150 | Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 863-869  | 4.6              | 21 |
|-----|---|------------------|----|
| 149 | Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. <i>Dermatology and Therapy</i> , <b>2014</b> , 4, 1-9   | 4                | 21 |
| 148 | Severe impairment of quality of life in Hailey-Hailey disease. <i>Acta Dermato-Venereologica</i> , <b>2005</b> , 85, 132  | <b>-5</b> .2     | 21 |
| 147 | Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e770-e772   | 4.6              | 21 |
| 146 | Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. <i>Drug Design, Development and Therapy,</i> <b>2016</b> , 10, 1763-70  | 4.4              | 21 |
| 145 | Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. <i>Journal of Dermatological Treatment</i> , <b>2018</b> , 29, 217-219  | 2.8              | 21 |
| 144 | Annular Lichenoid Dermatitis of Youth: Report of Six New Cases with Review of the Literature. <i>Dermatology</i> , <b>2015</b> , 231, 195-200   | 4.4              | 20 |
| 143 | Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 884-90  | 4                | 20 |
| 142 | Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and</i> | 4.6              | 19 |
| 141 | Venereology, <b>2015</b> , 29, 1156-63 Psodisk, a new visual method for assessing the burden of psoriasis on patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2012</b> , 26, 1163-6   | 4.6              | 19 |
| 140 | EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 281-3:   | 1 <del>7</del> 6 | 19 |
| 139 | Comparison of patientsRand providersReverity evaluation of oral mucosal conditions. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 69-76   | 4.5              | 18 |
| 138 | The diagnostic and therapeutic challenge of early psoriatic arthritis. <i>Dermatology</i> , <b>2010</b> , 221 Suppl 1, 6-14   | 4.4              | 17 |
| 137 | Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2129639   | 10.4             | 17 |
| 136 | Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 80-90   | 4                | 17 |
| 135 | Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , <b>2016</b> , 96, 251-2   | 2.2              | 17 |
| 134 | Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, e325-e326  | 4                | 16 |
| 133 | The pharmacological management of patients with comorbid psoriasis and obesity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 863-872  | 4                | 16 |

| 132 | Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. <i>Journal of Dermatology</i> , <b>2020</b> , 47, 578-582                       | 1.6 | 16 |
|-----|--|-----|----|
| 131 | Heat urticaria: a revision of published cases with an update on classification and management. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 473-8  | 4   | 16 |
| 130 | Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 133-136                            | 2.2 | 16 |
| 129 | Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.<br>Journal of Dermatological Science, 2015, 78, 149-51  | 4.3 | 15 |
| 128 | Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,   | 5.1 | 15 |
| 127 | Pruritus as a Distinctive Feature of Type 2 Inflammation. <i>Vaccines</i> , <b>2021</b> , 9,   | 5.3 | 15 |
| 126 | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. <i>Vaccines</i> , <b>2020</b> , 8,   | 5.3 | 14 |
| 125 | Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. Journal of Rheumatology, <b>2010</b> , 37, 448-52   | 4.1 | 14 |
| 124 | Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. <i>Medical Ultrasonography</i> , <b>2018</b> , 20, 177-184               | 1.4 | 14 |
| 123 | Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. <i>Vaccines</i> , <b>2020</b> , 8,  | 5.3 | 13 |
| 122 | Management of patients with psoriasis treated with biological drugs needing a surgical treatment.<br>Drug Development Research, <b>2014</b> , 75 Suppl 1, S24-6  | 5.1 | 13 |
| 121 | Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 749-751 | 7.1 | 13 |
| 120 | Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 409-410                              | 4   | 13 |
| 119 | Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation. <i>Dermatologic Therapy</i> , <b>2019</b> , 32, e13091                           | 2.2 | 12 |
| 118 | Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis. <i>Drug Development Research</i> , <b>2014</b> , 75 Suppl 1, S31-4           | 5.1 | 12 |
| 117 | An itchy vesiculobullous eruption in a patient with chronic lymphocytic leukaemia. <i>International Journal of Clinical Practice</i> , <b>2004</b> , 58, 1177-9  | 2.9 | 11 |
| 116 | Erythema nodosum: etiological factors and relapses in a retrospective cohort study. European Journal of Dermatology, <b>2010</b> , 20, 773-7   | 0.8 | 11 |
| 115 | Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 235-252                        | 4   | 11 |

| 114 | Primary Cutaneous CD4 Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2017</b> , 21, 502-506  | 1.6 | 10 |
|-----|--|-----|----|
| 113 | Concept of Remission in Chronic Plaque Psoriasis. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 57-60   |     | 10 |
| 112 | Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. <i>Journal of Dermatological Treatment</i> , <b>2006</b> , 17, 172-5  | 2.8 | 10 |
| 111 | Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 305-311                 | 5.3 | 10 |
| 110 | Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 671-680   | 4.5 | 10 |
| 109 | The psoriatic patient profile for infliximab. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2011</b> , 15, 1445-51  | 2.9 | 10 |
| 108 | Patients with psoriasis have a higher prevalence of parental cardiovascular disease. <i>Dermatology</i> , <b>2011</b> , 222, 330-5   | 4.4 | 9  |
| 107 | Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review.<br>Dermatology and Therapy, <b>2021</b> , 11, 695-705  | 4   | 9  |
| 106 | Impact of TNF-lantagonists on the quality of life in selected skin diseases. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2013</b> , 148, 243-8  | 0.8 | 9  |
| 105 | Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 2119-2123                       | 4.6 | 8  |
| 104 | Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. <i>Dermatologic Therapy</i> , <b>2017</b> , 30, e12503  | 2.2 | 8  |
| 103 | Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 397-398                                   | 4   | 8  |
| 102 | A systematic review of treatments for pityriasis lichenoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 2039-2049  | 4.6 | 8  |
| 101 | Effects of secukinumab on serum adipocytokines: preliminary data. <i>Reumatismo</i> , <b>2017</b> , 69, 105-110  | 1.1 | 8  |
| 100 | Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,   | 2.4 | 8  |
| 99  | Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 247-253   | 4.4 | 8  |
| 98  | Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 515-528   | 4.6 | 8  |
| 97  | PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 1310-7 | 4.6 | 7  |

| 96 | PatientsRperspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. <i>Journal of Dermatological Treatment</i> , <b>2017</b> , 28, 390-393                   | 2.8          | 7 |
|----|--|--------------|---|
| 95 | Hyperuricemia in patients with chronic plaque psoriasis. <i>Drug Development Research</i> , <b>2014</b> , 75 Suppl 1, S70-2  | 5.1          | 7 |
| 94 | Psoriasis and metabolic comorbidities: the importance of well-designed prospective studies. Commentary. <i>Dermatology</i> , <b>2008</b> , 217, 222-4  | 4.4          | 7 |
| 93 | Psoriasis and risk of myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 361-2; author reply 362-3  | 27.4         | 7 |
| 92 | TNF-Inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 591-598   | 5.1          | 7 |
| 91 | Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1502-1503   | 4            | 7 |
| 90 | Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatology and Therapy, <b>2020</b> , 7, 271-2  | <b>8</b> 5.4 | 7 |
| 89 | Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 693-700                             | 4.6          | 7 |
| 88 | Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , <b>2018</b> , 35, 545-562   | 4.1          | 6 |
| 87 | Kyrleß disease effectively treated with oral isotretinoin. <i>Journal of Dermatological Treatment</i> , <b>2018</b> , 29, 630-632  | 2.8          | 6 |
| 86 | Glomerular filtration rate in patients with psoriasis treated with etanercept. <i>Journal of International Medical Research</i> , <b>2016</b> , 44, 106-108  | 1.4          | 6 |
| 85 | A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. <i>Clinical and Experimental Dermatology</i> , <b>2009</b> , 34, 304-8  | 1.8          | 6 |
| 84 | Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14281   | 2.2          | 6 |
| 83 | Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e361-e362   | 4.6          | 6 |
| 82 | Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 572-581 | 4.5          | 6 |
| 81 | Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2013</b> , 148, 1-10   | 0.8          | 6 |
| 80 | Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 1319-1320   | 4            | 5 |
| 79 | Skin rash and arthritis a simplified appraisal of less common associations. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2014</b> , 28, 679-88   | 4.6          | 5 |

# (2020-2017)

| 78 | Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. <i>Italian Journal of Dermatology and Venereology</i> , <b>2017</b> , 152, 327-332   | 1.2          | 5 |
|----|--|--------------|---|
| 77 | Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,  | 5.1          | 5 |
| 76 | Impact of the COVID-19 pandemic on melanoma diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e714-e715   | 4.6          | 5 |
| 75 | IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14889   | 2.2          | 5 |
| 74 | Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 797-806 | 4.6          | 5 |
| 73 | Attitude to treatment of patients with psoriasis attending spa center. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2012</b> , 147, 483-9  | 0.8          | 5 |
| 72 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <i>Journal of Dermatological Treatment</i> , <b>2017</b> , 28, 129-135   | 2.8          | 4 |
| 71 | Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 1512-1520   | 2.3          | 4 |
| 70 | Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2839-2845   | 4.6          | 4 |
| 69 | Brodalumab in the treatment of chronic plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 1175-1186   | 5.4          | 4 |
| 68 | Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. <i>Acta Dermato-Venereologica</i> , <b>2016</b> , 96, 96-101   | 2.2          | 4 |
| 67 | Treatment of psoriasis with efalizumab in patients with hepatitis C viral infection: report of five cases. <i>Dermatology</i> , <b>2009</b> , 219, 158-61  | 4.4          | 4 |
| 66 | Hidradenitis suppurativa and adalimumab in the COVID-19 era. <i>European Journal of Dermatology</i> , <b>2020</b> , 30, 748-749  | 0.8          | 4 |
| 65 | Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1333-1343  | 4            | 4 |
| 64 | Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. <i>Journal of Investigative Dermatology</i> , <b>2021</b> ,                           | 4.3          | 4 |
| 63 | Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , <b>2020</b> , 236, 329-335  | 4.4          | 3 |
| 62 | Consensus on the place in therapy of TNF-IInhibitors in the treatment of patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e470-e472   | <b>.</b> 4.6 | 3 |
| 61 | Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13979  | 2.2          | 3 |

| 60 | A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 481-491                                      | 3.8                  | 3 |
|----|---|----------------------|---|
| 59 | The multidimensional burden of psoriasis. British Journal of Dermatology, 2018, 179, 13-14  | 4                    | 3 |
| 58 | A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2019</b> , 154, 392-399            | 0.8                  | 3 |
| 57 | Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1 | 5.2                  | 3 |
| 56 | How to improve adherence to treatment in patients with mild-to-moderate psoriasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , <b>2018</b> , 153, 692-697   | 0.8                  | 3 |
| 55 | Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 199, 88-96  | 6.2                  | 3 |
| 54 | Clinical features and treatments of transient acantholytic dermatosis (Grover® disease): a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2020</b> , 18, 826-833                            | 1.2                  | 3 |
| 53 | Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Dermatology</i> , <b>2021</b> , 237, 929-933  | 4.4                  | 3 |
| 52 | Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e636           | 5- <del>4</del> -640 | 3 |
| 51 | Disseminated lupus vulgaris. European Journal of Dermatology, <b>2003</b> , 13, 500-2   | 0.8                  | 3 |
| 50 | Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2014</b> , 18, 3435-52   | 2.9                  | 3 |
| 49 | Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor-Ito interleukin-17A inhibitor. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 624-626                         | 4                    | 2 |
| 48 | Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series.<br>Journal of the European Academy of Dermatology and Venereology, <b>2019</b> , 33, e246-e247                                | 4.6                  | 2 |
| 47 | Combination of efalizumab and acitretin in chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2008</b> , 22, 247-8  | 4.6                  | 2 |
| 46 | Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. <i>Italian Journal of Dermatology and Venereology</i> , <b>2021</b> , 156, 455-459                          | 1.2                  | 2 |
| 45 | Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study.  Dermatologic Therapy, <b>2021</b> , 34, e14949   | 2.2                  | 2 |
|    |   |                      |   |
| 44 | Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. <i>BioDrugs</i> , <b>2021</b> , 35, 469-471  | 7.9                  | 2 |

## (2021-2019)

| 42 | The multifaceted association between psoriasis and obesity. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 24   | 4   | 2 |
|----|---|-----|---|
| 41 | Does systemic treatment of psoriasis reduce the risk of comorbidities?. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 823-824  | 4   | 2 |
| 40 | Increased red blood cell distribution width in patients with plaque psoriasis. <i>Journal of Medical Biochemistry</i> , <b>2021</b> , 40, 199-201   | 1.9 | 2 |
| 39 | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. <i>Vaccines</i> , <b>2022</b> , 10, 646   | 5.3 | 2 |
| 38 | Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 175-179   | 4   | 1 |
| 37 | AB0821 Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1174-1174   | 2.4 | 1 |
| 36 | Biological agents targeting interleukin-13 for atopic dermatitis <i>Expert Opinion on Biological Therapy</i> , <b>2022</b> ,  | 5.4 | 1 |
| 35 | Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey <i>British Journal of Dermatology</i> , <b>2022</b> ,   | 4   | 1 |
| 34 | Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2168-2169  | 4.6 | 1 |
| 33 | Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,  | 3.6 | 1 |
| 32 | Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e355-e357   | 4.6 | 1 |
| 31 | Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e709-e711 | 4.6 | 1 |
| 30 | VISUAL VIGNETTE. Endocrine Practice, <b>2020</b> , 26, 253  | 3.2 | 1 |
| 29 | Place of apremilast in the real-life treatment of patients with plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 13  | 4.6 | 1 |
| 28 | Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. <i>Acta Dermato-Venereologica</i> , <b>2021</b> , 101, adv00576   | 2.2 | 1 |
| 27 | Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study. <i>Acta Dermato-Venereologica</i> , <b>2021</b> , 101, adv00422  | 2.2 | 1 |
| 26 | Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products. <i>Clinical and Experimental Dermatology</i> , <b>2021</b> ,  | 1.8 | 1 |
| 25 | Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,   | 4.5 | 1 |

| 24 | The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 1099-1107   | 2.2 | 1 |
|----|--|-----|---|
| 23 | Is risankizumab as needed administration a good option for patients with plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> ,  | 4.6 | 1 |
| 22 | Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e04153  | 0.7 | 0 |
| 21 | Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. <i>Global &amp; Regional Health Technology Assessment</i> ,8, 120-130  | 0.2 | O |
| 20 | Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis <i>Italian Journal of Dermatology and Venereology</i> , <b>2022</b> , 157, 1-78  | 1.2 | O |
| 19 | Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2021</b> , 12034754211066906                         | 1.6 | O |
| 18 | Could maternal stress increase the risk of developing psoriasis in the offspring?. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 569-570  | 4   |   |
| 17 | Is the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis?. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 262-263  | 4   |   |
| 16 | Skin moisturization for xerosis related to targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, e33  | 4.5 |   |
| 15 | Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. <i>Vaccine</i> , <b>2020</b> , 38, 3808-3809   | 4.1 |   |
| 14 | Image Gallery: Pyoderma gangrenosum of the penis. British Journal of Dermatology, 2018, 178, e62   | 4   |   |
| 13 | Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. <i>Journal of Dermatology</i> , <b>2017</b> , 44, e332-e333  | 1.6 |   |
| 12 | Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register.<br>British Journal of Dermatology, <b>2015</b> , 173, 329-30  | 4   |   |
| 11 | Skin adverse reactions to Sars-CoV-2 vaccination: a relevant responsibility issue for dermatologists <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> , 36, 165-166                                       | 4.6 |   |
| 10 | Predictors of subsequent primary melanoma: a case-control study. <i>Archives of Dermatological Research</i> , <b>2021</b> , 1  | 3.3 |   |
| 9  | Ki67/MART1 and p63/SOX10 Dual Immunohistochemistry Allows a Correct Interpretation of the Melanocytic Component in the Diagnosis of Pigmented Pilomatricoma <i>Indian Journal of Dermatology</i> , <b>2021</b> , 66, 525-529                 | 0.9 |   |
| 8  | SAT0412 ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENTS: RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR RHEUMATOLOGICAL REFERRAL OF PSORIATIC SUBJECTS AIMED TO DISCLOSE | 2.4 |   |
| 7  | PSORIATIC ARTHRITIS). Annals of the Rheumatic Diseases, 2020, 79, 1158.2-1159  Metabolic Syndrome in Psoriasis 2010, 95-98   |     |   |

#### LIST OF PUBLICATIONS

| 6 | Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature. <i>Case Reports in Dermatology</i> , <b>2021</b> , 13, 282-288   | 1.1                        |
|---|---|----------------------------|
| 5 | Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , <b>2021</b> , 1-7  | 4.4                        |
| 4 | Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> ,                           | 4.6                        |
| 3 | In vitro cell culture of amniotic fluid keratinocytes on amniotic membrane: the ideal tissue for repairing skin ulcers. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2021</b> , 25, 49-55 | 2.9                        |
| 2 | Paradoxical Effect on Epidermal Barrier of Anti-TNF-alpha Treatment for Psoriasis <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2022</b> , 15, 36-38  | 1.2                        |
| 1 | Scurvy as Presenting Sign of Anorexia Nervosa <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2022</b> , 120  | 347 <del>54</del> 22110019 |